Langerhans cell histiocytosis (LCH) is a rare myeloid neoplasm characterized by clonal proliferation of Langerhans-type dendritic cells. When LCH involves the hypothalamic-pituitary axis, it can cause significant endocrine dysfunction, diabetes insipidus, and various neurological manifestations. The impact on hypothalamic neurons and the resulting neuroendocrine disturbances represent a significant clinical challenge. [1]
LCH represents a spectrum of disease ranging from single-system局限性 disease to multisystem involvement. Central nervous system (CNS) involvement, particularly of the hypothalamic-pituitary axis, occurs in approximately 30-50% of patients with multisystem LCH [1]. The resulting endocrine dysfunction can profoundly affect quality of life and requires long-term management. [2]
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:0000453 | Langerhans cell |
| Database | ID | Name | Confidence | [3]
|----------|----|------|------------| [4]
| Cell Ontology | CL:0000453 | Langerhans cell | Medium |
| Cell Ontology | CL:4042028 | immature neuron | Medium |
LCH results from clonal proliferation of cells bearing the phenotype of Langerhans dendritic cells:
The most common CNS manifestation of LCH is diabetes insipidus caused by vasopressin (AVP) neuron dysfunction:
GH deficiency is the second most common endocrine dysfunction:
Central hypothyroidism occurs through:
Hypogonadotropic hypogonadism results from:
A subset of patients develop a neurodegenerative syndrome:
The BRAF V600E mutation is central to LCH pathogenesis:
| Feature | Details |
|---|---|
| Prevalence | ~50% of LCH cases |
| Detection | Immunohistochemistry, PCR, sequencing |
| Prognostic significance | Higher recurrence risk |
| Targeted therapy | Vemurafenib, dabrafenib |
MRI findings:
| Deficiency | Treatment |
|---|---|
| Diabetes insipidus | Desmopressin (DDAVP) |
| Growth hormone | Recombinant GH |
| Hypothyroidism | Levothyroxine |
| Hypogonadism | Sex steroid replacement |
| Adrenal insufficiency | Glucocorticoid replacement |
](/cell-types/diabetes-insipidus-neurons
--hypothalamic-neurons
--posterior-pituitary
--central-endocrine-disorders
--braf-v600e-neurons)## Background
The study of Hypothalamic Neurons In Langerhans Cell Histiocytosis has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Grois N, Pötschger U, Prosch H, et al. Risk factors for diabetes insipidus in Langerhans cell histiocytosis. Pediatr Blood Cancer. 2006. 2006. ↩︎
Makras P, Alexandraki KI, Chrousos GP, et al. Endocrine manifestations of Langerhans cell histiocytosis. Horm Metab Res. 2008. 2008. ↩︎
Hutter C, Minkov M. Insights into the pathogenesis of Langerhans cell histiocytosis: The role of BRAF and MAPK pathway. J Pediatr Hematol Oncol. 2018. 2018. ↩︎
Grois N, Fahrner B, Arceci RJ, et al. Central nervous system disease in Langerhans cell histiocytosis. J Pediatr. 2010. 2010. ↩︎